Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Depreciation and Depletion (2023 - 2025)

Mangoceuticals' Depreciation and Depletion history spans 3 years, with the latest figure at $255.0 for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion changed 0.0% to $255.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1012.0, a 89.81% decrease, with the full-year FY2025 number at $1012.0, down 89.81% from a year prior.
  • Depreciation and Depletion hit $255.0 in Q4 2025 for Mangoceuticals, roughly flat from $255.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for MGRX hit a ceiling of $6292.0 in Q3 2023 and a floor of $250.0 in Q1 2025.
  • Historically, Depreciation and Depletion has averaged $2986.4 across 3 years, with a median of $1730.0 in 2024.
  • The widest YoY moves for Depreciation and Depletion: up 2.33% in 2024, down 95.99% in 2024.
  • Tracing MGRX's Depreciation and Depletion over 3 years: stood at $6291.0 in 2023, then tumbled by 95.95% to $255.0 in 2024, then changed by 0.0% to $255.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for MGRX at $255.0 in Q4 2025, $255.0 in Q3 2025, and $252.0 in Q2 2025.